Myriad Genetics (MYGN) Misses Q1 EPS by 2c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
November 1, 2016 4:05 PM EDTTotal Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance
SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2017, provided an update on recent business highlights, Â maintained its fiscal year 2017 financial guidance and issued fiscal second-quarter 2017 financial guidance.Â
"We were pleased with the first quarter as our hereditary cancer business returned to more normal... More
